CLINICAL_TRIALS ClinicalTrials.gov record update

Efficacy and Safety of Furmonertinib in Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases: A Prospective, Open-label, Phase II Trial（iFORCE）

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05465343
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:47.261929+00:00
Published At: 2025-12-19T00:00:00+00:00
Record Updated At: 2025-12-19
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Furmonertinib", "EGFR-mutation", "NSCLC", "Brain Metastases"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-12-19"
protocolSection.identificationModule.nctId: "NCT05465343"
protocolSection.identificationModule.officialTitle: "Efficacy and Safety of Furmonertinib in Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases: A Prospective, Open-label, Phase II Trial\uff08iFORCE\uff09"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.